Bionoid Pharma Financials
| BINP Stock | USD 0.11 0.09 45.00% |
Bionoid |
Understanding current and past Bionoid Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bionoid Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Bionoid Pharma's assets may result in an increase in income on the income statement.
Bionoid Pharma Stock Summary
Bionoid Pharma competes with Smith Douglas, United Homes, JBG SMITH, Treasury Wine, and MI Homes. Bionoid Pharma Inc. engages in the hemp cultivation business. Bionoid Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 5 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 433 North Camden, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | bionoidpharma.com |
| Phone | 800 784 7641 |
| Currency | USD - US Dollar |
Bionoid Pharma Key Financial Ratios
Bionoid Pharma's financial ratios allow both analysts and investors to convert raw data from Bionoid Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Bionoid Pharma over time and compare it to other companies across industries.Bionoid Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bionoid Pharma's current stock value. Our valuation model uses many indicators to compare Bionoid Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bionoid Pharma competition to find correlations between indicators driving Bionoid Pharma's intrinsic value. More Info.Bionoid Pharma is number one stock in return on asset category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionoid Pharma's earnings, one of the primary drivers of an investment's value.Bionoid Pharma Systematic Risk
Bionoid Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bionoid Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Bionoid Pharma correlated with the market. If Beta is less than 0 Bionoid Pharma generally moves in the opposite direction as compared to the market. If Bionoid Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bionoid Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bionoid Pharma is generally in the same direction as the market. If Beta > 1 Bionoid Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Bionoid Pharma November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bionoid Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bionoid Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bionoid Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Bionoid Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bionoid Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | 0.0438 | |||
| Maximum Drawdown | 85.0 | |||
| Value At Risk | (10.00) | |||
| Potential Upside | 25.0 |
Additional Tools for Bionoid Pink Sheet Analysis
When running Bionoid Pharma's price analysis, check to measure Bionoid Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionoid Pharma is operating at the current time. Most of Bionoid Pharma's value examination focuses on studying past and present price action to predict the probability of Bionoid Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionoid Pharma's price. Additionally, you may evaluate how the addition of Bionoid Pharma to your portfolios can decrease your overall portfolio volatility.